<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228760</url>
  </required_header>
  <id_info>
    <org_study_id>ASG-5ME-10-1</org_study_id>
    <nct_id>NCT01228760</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD)&#xD;
      and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate&#xD;
      cancer (CRPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has two components. The first aims to establish a safe dose of ASG-5ME. Once&#xD;
      identified, the safety and preliminary estimate of antitumor activity of ASG-5ME will be&#xD;
      tested in additional subjects with castration-resistant prostate cancer (CRPC) who are either&#xD;
      chemotherapy naïve or chemotherapy exposed in expanded cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by recording of adverse events, laboratory assessments and vital signs</measure>
    <time_frame>For 12 weeks during treatment period and up to 4 weeks follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics assessment of ASG-5ME blood levels through analysis of blood samples</measure>
    <time_frame>Up to day 15 for cycle 1 and cycle 4 and pre-dose for cycles 2 and 3; every 3 weeks during the second 12 weeks of treatment; and if subject continues on study drug, every 12 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-ASG-5ME antibody formation</measure>
    <time_frame>Baseline; up to day 64 during the first 12 weeks; and if subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of tumor response (complete or partial response)</measure>
    <time_frame>Baseline and every 12 weeks while on study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prostate-specific antigen (PSA) levels</measure>
    <time_frame>Baseline; up to day 64 during the first 12 weeks; and if the subject continues on study drug, every 3 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone scans</measure>
    <time_frame>Baseline and every 12 weeks while on study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in circulating tumor cells</measure>
    <time_frame>Baseline; up to day 64 during the first 12 weeks; and if the subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokeratin-18 levels</measure>
    <time_frame>Up to day 79 and 4 weeks after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Prostate Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy-naïve subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy exposed subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASG-5ME</intervention_name>
    <description>IV</description>
    <arm_group_label>Chemotherapy exposed subjects</arm_group_label>
    <arm_group_label>Chemotherapy-naïve subjects</arm_group_label>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 5A</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_label>Dose level 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has histologically-confirmed castration-resistant prostate cancer and meets at&#xD;
             least 1 of the following criteria:&#xD;
&#xD;
               -  subject's disease has progressed on or after available standard therapy -OR-&#xD;
&#xD;
               -  there is no effective standard therapy available for treating the subject's&#xD;
                  disease -OR-&#xD;
&#xD;
               -  subject or his disease is not suitable for standard therapy -OR-&#xD;
&#xD;
               -  subject chooses to defer or decline standard therapy (subject is adequately&#xD;
                  informed of the availability of clinically meaningful therapy and chooses instead&#xD;
                  to partake in this research using a product with no documented clinical activity)&#xD;
&#xD;
          -  Testosterone ≤ 50 ng/dL&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy of &gt; 6 months as evaluated and documented by the investigator&#xD;
&#xD;
          -  Hematologic function, as follows (no red blood cell (RBC) or platelet transfusions are&#xD;
             allowed within 4 weeks of the first dose of ASG-5ME):&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Renal function, as follows: creatinine ≤ 1.5 x upper limit of normal (ULN), or&#xD;
             creatinine clearance of &gt; 60 mL/min if serum creatinine is &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 1. 5 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)≤ 1.5 x ULN&#xD;
&#xD;
          -  International Normalized Ratio (INR) &lt; 1.3 (or &lt; 3.0 if on therapeutic&#xD;
             anticoagulation)&#xD;
&#xD;
          -  Serum calcium ≤ ULN&#xD;
&#xD;
          -  Subjects must be taking and agree to remain on a stable dose of luteinizing&#xD;
             hormone-releasing hormone (LHRH) agonist therapy or gonadotropin-releasing hormone&#xD;
             (GnRH) antagonist for the duration of the trial if not surgically castrated&#xD;
&#xD;
          -  Additional Inclusion criteria for Chemotherapy Naïve Cohort: No prior systemic&#xD;
             cytotoxic chemotherapies&#xD;
&#xD;
          -  Additional Inclusion criteria for Chemotherapy Exposed Cohort:&#xD;
&#xD;
               -  Documented disease progression during or after docetaxel treatment or&#xD;
                  intolerability to docetaxel treatment&#xD;
&#xD;
               -  No additional prior chemotherapy for CRPC is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of central nervous system metastasis, including incompletely treated epidural&#xD;
             disease&#xD;
&#xD;
          -  History of other primary malignancy (including premalignant myeloid malignancy e.g.&#xD;
             myelodysplastic syndrome), unless:&#xD;
&#xD;
               -  Curatively resected non-melanomatous skin cancer&#xD;
&#xD;
               -  Other malignancy curatively treated with no known active disease present and no&#xD;
                  treatment administered for the last 3 years&#xD;
&#xD;
          -  Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart&#xD;
             Association CHF Functional Classification System) or clinically significant cardiac&#xD;
             disease within 12 months of study enrollment, including myocardial infarction,&#xD;
             unstable angina, grade 2 or greater peripheral vascular disease, congestive heart&#xD;
             failure, uncontrolled hypertension, or arrhythmias not controlled by outsubject&#xD;
             medication&#xD;
&#xD;
          -  The following treatments are not allowed within 4 weeks of enrollment: cytotoxic&#xD;
             chemotherapy, radiation therapy or the dietary supplement PC-SPES&#xD;
&#xD;
          -  Use of prednisone (or equivalent corticosteroids) &gt; 20 mg/day are not allowed. Doses &lt;&#xD;
             20 mg/day are allowed only if they have been at the same dose for &gt; 4 weeks&#xD;
&#xD;
          -  Use of anti-androgen therapy (ie, flutamide, bicalutamide and nilutamide) within 6&#xD;
             weeks of study enrollment; non-responders to second-line anti-androgen therapy do not&#xD;
             require the 6 week withdrawal period&#xD;
&#xD;
          -  Monoclonal antibody therapy within 3 months of enrollment with the exception of&#xD;
             denosumab (prior or concurrent use of denosumab is allowed)&#xD;
&#xD;
          -  Peripheral neuropathy of ≥ grade 2 as defined by the CTCAE criteria version 4.0&#xD;
&#xD;
          -  Major surgery (that requires general anesthesia) within 4 weeks of study enrollment&#xD;
&#xD;
          -  Active infection requiring treatment with systemic (intravenous or oral)&#xD;
             anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of&#xD;
             screening&#xD;
&#xD;
          -  Use of any investigational drug (including marketed drugs not approved for this&#xD;
             indication) within 30 days prior to enrollment&#xD;
&#xD;
          -  History of thromboembolic events and bleeding disorders ≤ 3 months (e.g., deep vein&#xD;
             thrombosis (DVT) or pulmonary embolism (PE))&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis&#xD;
             B surface antigen&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Agensys, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Karmanos Cancer Institute</name>
      <address>
        <city>Detriot</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Madison, Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>June 6, 2013</last_update_submitted>
  <last_update_submitted_qc>June 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castration-Resistant Prostate Cancer</keyword>
  <keyword>ASG-5ME</keyword>
  <keyword>Pharmacokinetics of ASG-5ME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

